Across TCGA pan-cancer cohorts, MED15P6 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MED15P6’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where MED15P6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MED15P6 is over-expressed in tumor.
PRAD are the cancer types where MED15P6 tumor–normal differential expression is most reproducible.